On August 22^nd, 2025, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (Stock Code: 603392; “Wantai BioPharm”) announced that its wholly-owned subsidiary, Xiamen INNOVAX Biotech Co., Ltd. (INNOVAX), has received the Biological Products Batch Release Certificate from China’s National Institutes for Food and Drug Control (NIFDC) for its HPV 9-valent vaccine, Cecolin^®9.

This milestone marks the official market launch of the world’s second HPV 9-valent vaccine, now approved for commercial distribution in China— a step that also signifies the start of its global journey. The launch strengthens INNOVAX’s product portfolio by complementing its existing HPV bivalent vaccine (Cecolin^®), forming a differentiated portfolio to meet diverse public health needs, from foundational protection to broad-spectrum coverage. It expands access to high-quality HPV prevention, offering expanded choice to women worldwide.

About INNOVAX's Cecolin^® Series

INNOVAX's Cecolin^® Series, is the first HPV vaccine brand in developing country originating from China.

• Cecolin^® (HPV bivalent vaccine): Launched in China in 2019, as the world's second HPV bivalent vaccine and the first HPV vaccine from China, pre-qualified by WHO in 2021. As of July 2025, Cecolin^® has been licensed in 23 countries including 3 PIC/S GMP countries (Thailand, Indonesia, Mexico) and introduced into the National immunization program of 8 countries, including Thailand, Nicaragua, Nepal, Angola, Pakistan, Tunisia, Burundi and Cuba. In total, approaching 70 million doses have been distributed globally, benefiting more than 20 million females worldwide, with a proven excellent safety profile.

• Cecolin^® 9 (HPV 9-valent vaccine): Launch in China in 2025, Cecolin^® 9 is the second HPV 9-valent vaccine globally. As the next-generation HPV vaccine in the Cecolin^® series, it builds on the practical expertise Cecolin^® has accumulated in industrialization, global GMP compliance, and worldwide supply capabilities. In a head-to-head immunogenicity comparison clinical trial, a three-dose regimen of the Cecolin^® 9 was similarly immunogenic compared with a marketed HPV 9-valent vaccine , making it a potential candidate to accelerate the elimination of cervical cancer by allowing for global accessibility to HPV 9-valent vaccinations, especially in LMICs.

As an active implementer to global cervical cancer prevention, INNOVAX is taking concrete actions to advance WHO's 2030 public health goal of eliminating cervical cancer worldwide.